تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $6.5B | $6.1B | $5.4B | $6.0B | $5.4B | $5.2B | $4.4B | $4.3B | $3.7B | $3.4B | $3.0B | $2.5B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.3B | $1.2B | $1.1B | $1.0B |
| سود ناخالص | $5.1B | $4.7B | $4.3B | $4.6B | $4.2B | $4.0B | $3.3B | $3.2B | $2.8B | $2.6B | $2.2B | $1.8B | $1.7B | $1.5B | $1.4B | $1.2B | $1.0B | $922M | $829M | $710M | $654M |
| حاشیه سود ناخالص % | 78.0% | 78.1% | 79.5% | 77.0% | 78.3% | 76.6% | 74.9% | 73.4% | 75.2% | 74.3% | 72.8% | 72.6% | 72.8% | 73.4% | 73.3% | 72.5% | 71.7% | 69.8% | 67.0% | 65.0% | 63.0% |
| سود عملیاتی (EBIT) | $1.8B | $1.6B | $1.4B | $1.5B | $1.7B | $1.6B | $1.3B | $1.2B | $1.1B | $1.0B | $816M | $576M | $487M | $433M | $397M | $329M | $282M | $238M | $209M | $170M | $164M |
| حاشیه سود عملیاتی % | 28.1% | 27.0% | 25.4% | 25.6% | 31.6% | 30.8% | 29.5% | 27.6% | 29.3% | 29.4% | 27.5% | 23.1% | 21.0% | 21.2% | 20.9% | 19.6% | 19.5% | 18.0% | 16.9% | 15.5% | 15.8% |
| سود خالص | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B | $823M | $1.0B | $722M | $622M | $570M | $495M | $811M | $392M | $293M | $237M | $218M | $229M | $129M | $113M | $130M |
| حاشیه سود خالص % | 15.4% | 17.7% | 76.8% | 23.4% | 28.3% | 28.7% | 18.8% | 24.1% | 19.4% | 18.1% | 19.2% | 19.9% | 34.9% | 19.1% | 15.4% | 14.1% | 15.1% | 17.3% | 10.4% | 10.4% | 12.6% |
| EBITDA | — | $1.4B | $1.7B | $1.5B | $2.0B | $1.9B | $1.1B | $1.3B | $872M | $1.1B | $827M | $707M | $1.2B | $590M | $453M | $345M | $327M | $297M | $227M | $214M | $240M |
| سود هر سهم (EPS) | $1.74 | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $0.96 | $0.87 | $0.75 | $1.25 | $0.57 | $0.41 | $0.33 | $0.30 | $0.33 | $0.18 | $0.15 | $0.17 |
| سهام منتشرشده (میلیون) | — | 586M | 599M | 609M | 624M | 631M | 632M | 637M | 641M | 648M | 653M | 661M | 651M | 683M | 710M | 716M | 715M | 704M | 715M | 752M | 767M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی EW در دسترس است. /companies/us/EW
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms